Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine

AIDS Research and Human Retroviruses

Volumn 25, Issue 10, 2009, Pages 989-996

  Musiime, Victor ^a   Ssali, Francis ^a   Kayiwa, Joshua ^a   Namala, Winnie ^a   Kizito, Hilda ^a   Kityo, Cissy ^a   Mugyenyi, Peter ^a  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PERINATAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NEVIRAPINE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70449478941     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0054     Document Type: Article

References (23)

1. Jackson JB, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-868.
2. Eshleman SH, Hoover DR, Chen S, et al.: Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005;19:2167-2169.
3. Flys TS, McConnell MS, Matovu F, et al.: Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis 2008;198:465-469.
4. Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, and Paranjape RS: Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. AIDS Res Hum Retroviruses 2007;23:682-685.
5. Simpore J, Pietra V, Savadogo A, et al.: Reduction of motherto-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso. J Med Virol 2006;78:148-152.
6. Kassaye S, Lee E, Kantor R, et al.: Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: Population and clonal sequence analysis. AIDS Res Hum Retroviruses 2007;23:1055-1061.
7. Lee EJ, Kantor R, Zijenah L, et al.: Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to singledose nevirapine. J Infect Dis 2005;192:1260-1264.
8. Toni TD, Masquelier B, Lazaro E, et al.: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005;21:1031-1034.
9. Lockman S, Shapiro RL, Smeaton LM, et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147.
10. Barlow-Mosha L, Ajunua P, Mubiru M, et al.: Early Effectiveness of a NVP-based HAART regimen among HIVinfected children with and without prior single-dose NVP exposure. In: 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008.
11. World Health Organization: Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. World Health Organization, Geneva, Switzerland, 2006.
12. Arrive E, Newell ML, Ekouevi DK, et al.: Prevalence of resistance to nevirapine in mothers and children after singledose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol 2007;36:1009-1021.
13. Chaix ML, Ekouevi DK, Peytavin G, et al.: Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007;51:896-901.
14. Church JD, Omer SB, Guay LA, et al.: Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008;198:1075-1082.
15. Eshleman SH, Hoover DR, Hudelson SE, et al.: Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006;193:479-481.
16. Martinson NA, Morris L, Gray G, et al.: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
17. Prendergast A, Mphatswe W, Tudor-Williams G, et al.: Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008;22:1333-1343.
18. Turriziani O, Russo G, Lichtner M, et al.: Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008;24:781-785.
19. Coffie PA, Ekouevi DK, Chaix ML, et al.: Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008;46:611-621.
20. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-240.
21. Clinical Care Options: Pocket Guide to Antiretroviral Resistance Mutations. Clinical Care Options, Reston, VA.
22. World Health Organization: WHO Technical Reference Group Paediatric HIV CARE ART Guideline Review meeting. World Health Organization, Geneva, Switzerland, 2008.
23. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009, pp. 1-139. Available at http:==aidsinfo.nih.gov=ContentFiles=PediatricGuidelines.pdf. Accessed May 29, 2009.